ArticleBritish journal of clinical pharmacology2022

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.

Helena Edlund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.